Wesana inks a multi-year research agreement with the World Boxing Council on psychedelics therapy for Traumatic Brain Injury (TBI).

A new study out of Washington State University suggests cannabis may inspire entrepreneurs to come up with big, bold business ideas—but could also lead them down a rabbit hole of wishful thinking.

Since retiring from the National Hockey League in 2015 at age 30, Daniel Carcillo has dedicated his life to helping athletes and other people like himself who have suffered from traumatic brain injury.

Compass Pathways highlights for Q1 include two new patents and reports its Phase IIb clinical trial is on track.

Numinus fills several key roles including a new Director of Mergers and Acquisitions and a new Chief Communications Officer.

Traumatic Brain Injury is another major treatment market targeted by psychedelics R&D. TBIs are now a health crisis in many professional sports. Opportunity knocks.

MindMed reports a net loss of CAD$14 million for Q1, with US$160 million in cash and a total cash burn for the quarter of CAD$10 million.

It’s been a long, strange trip in the four decades since Rick Doblin, a pioneering psychedelics researcher, dropped his first hit of acid in college and decided to dedicate his life to the healing powers of mind-altering compounds.

For a solid month, there has been an explosion in coverage of the psychedelic drug industry by the mainstream media.

Psychedelic drug stocks are a very progressive investing option for investors seeking high-growth opportunities. So why aren’t more Millennials jumping on the bandwagon?